...
首页> 外文期刊>BMC Nephrology >A simple tourniquet technique for bleeding control after percutaneous hemodialysis fistula and graft interventions
【24h】

A simple tourniquet technique for bleeding control after percutaneous hemodialysis fistula and graft interventions

机译:经皮血液透析瘘和移植干预后的出血控制简单止血带技术

获取原文
           

摘要

The purse-string suture has been widely used for bleeding control after percutaneous interventions through arteriovenous fistula (AVF) and graft (AVG), and it requires suture removal the next day. This study aimed to introduce a simple method using a tourniquet to facilitate hemostasis following AVF or AVG sheath removal after percutaneous procedures. Data were retrospectively collected and included all the consecutive patients who received bleeding control with a tourniquet after percutaneous AVF or AVG interventions. Hemostasis was facilitated using the tourniquet technique after sheath removal. A total of 1966 patients who received the tourniquet technique for bleeding control after percutaneous AVF or AVG interventions were included. Bleeding control was successfully achieved in all patients. Regarding complications, hematoma, thrombosis, and rebleeding occurred in 57 (2.9%), 11 (0.6%), and 8 (0.4%) patients, respectively. Neither pseudoaneurysm nor infection occurred in the patients. Age, gender, pre-existing diseases (including diabetes and hypertension), procedure count, sheath size, hemodialysis access type, and canalization route were similar between patients with and without complications. The primary patency rates at 6,12, 24, and 36?months were 85.0, 64.6, 53.8, and 41.6%, respectively. The tourniquet technique is an effective and safe approach for facilitating hemostasis after catheter-based percutaneous interventions of hemodialysis accesses.
机译:用动静脉瘘(AVF)和移植物(AVG)经皮干预后,Purse串缝合线已被广泛用于出血控制,并且在第二天需要缝合缝合。本研究旨在引入一种使用止血带的简单方法,以便在经皮程序后进行AVF或AVG鞘移除后止血。回顾性地收集数据,并包括所有连续的患者,在经皮AVF或AVG干预后用止血带接受出血控制的所有连续患者。鞘拆除后使用止血带技术促进了止血。包括1966名接受止血带技术的1966名患者,在经皮AVF或AVG干预后出血控制。所有患者都成功实现了出血控制。关于在57(2.9%),11(0.6%)和8(0.4%)患者中发生的并发症,血肿,血栓形成和再混凝土发生。患者既不发生伪肿瘤也不发生感染。年龄,性别,预先存在的疾病(包括糖尿病和高血压),程序计数,鞘尺寸,血液透析接入型和可患者之间的患者与无和并发症之间的相似性。 6,12,24和36个月的主要通用率分别为85.0,64.6,53.8和41.6%。止血带技术是一种有效且安全的方法,可促进血液透析通道的导管经皮干预后的止血。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号